Abstract

Vaccine trials and cohort studies in Plasmodium falciparum endemic areas indicate that naturally-acquired and vaccine-induced antibodies to merozoite surface protein 2 (MSP2) are associated with resistance to malaria. These data indicate that PfMSP2 has significant potential as a component of a multi-antigen malaria vaccine. To overcome challenges encountered with subunit malaria vaccines, we established that the use of highly immunogenic rPfMSP8 as a carrier protein for leading vaccine candidates rPfMSP119 and rPfs25 facilitated antigen production, minimized antigenic competition and enhanced induction of functional antibodies. We applied this strategy to optimize a rPfMSP2 (3D7)-based subunit vaccine by producing unfused rPfMSP2 or chimeric rPfMSP2/8 in Escherichia coli. rPfMSP2 formed fibrils, which induced splenocyte proliferation in an antigen receptor-independent, TLR2-dependent manner. However, fusion to rPfMSP8 prevented rPfMSP2 amyloid-like fibril formation. Immunization of rabbits elicited high-titer anti-PfMSP2 antibodies that recognized rPfMSP2 of the 3D7 and FC27 alleles, as well as native PfMSP2. Competition assays revealed a difference in the specificity of antibodies induced by the two rPfMSP2-based vaccines, with evidence of epitope masking by rPfMSP2-associated fibrils. Rabbit anti-PfMSP2/8 was superior to rPfMSP2-elicited antibody at opsonizing P. falciparum merozoites for phagocytosis. These data establish rPfMSP8 as an effective carrier for a PfMSP2-based subunit malaria vaccine.

Highlights

  • Throughout the past several years, great progress has been made towards the goal of malaria elimination and eventual eradication with the widespread implementation of a number of control strategies[1]

  • The mature coding sequence of the 3D7 allele of the pfmsp[2] gene was codon harmonized for expression in E. coli using previously established algorithms[45]

  • The codon harmonized synthetic gene was directionally subcloned into the pET28-MCS-PfMSP8(CΔS) expression vector to facilitate production of two recombinant PfMSP2-based antigens: an unfused rPfMSP2 antigen (25 kDa) and a chimeric rPfMSP2/8 antigen (68 kDa, Fig. 1A)

Read more

Summary

Introduction

Throughout the past several years, great progress has been made towards the goal of malaria elimination and eventual eradication with the widespread implementation of a number of control strategies[1]. Data from the most recent World Malaria Report indicate that the preceding decline in clinical cases of malaria and malaria-related deaths is beginning to level off in most regions and is even showing signs of reversal in others These data are concerning and are likely a result of increases in drug-resistant parasites and insecticide-resistant mosquitoes, along with the challenge of sustaining multiple control programs in endemic areas[1]. Through genetic fusion of the blood-stage vaccine candidate, PfMSP119, to the N-terminus of the conserved, highly immunogenic PfMSP8, we were able to produce high yields of chimeric rPfMSP1/8 antigen with properly folded EGF-like domains. This chimeric antigen approach prevented antigenic competition and the vaccine elicited high-titer antibodies specific for conformation-dependent, protective epitopes of PfMSP11916. The success with chimeric rPfMSP1/8 and rPfs25/8 vaccines with respect to production, folding, immunogenicity and induction of functional antibodies, prompted us to evaluate PfMSP8 as a fusion partner for another leading blood-stage vaccine candidate, P. falciparum MSP2

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call